Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Commentary
  • Published:

Fates intertwined

Nature Biotechnology volume 24, pages 252–254 (2006)Cite this article

Biotech will fundamentally reshape the pharmaceutical industry in the coming years. Garth Cooper, a veteran of the biotech industry, explains why.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: The number of small-molecule drugs, recombinant proteins and monoclonal antibody therapeutics approved in the United States during 1980–2001.

References

  1. Fishman, M.C. & Porter, J.A. Nature 437, 491–493 (2005).

    Article  CAS  Google Scholar 

  2. Couzin, J. Science 309, 728–730 (2005).

    Article  CAS  Google Scholar 

  3. http://www.gatesfoundation.org/GlobalHealth

  4. Cordwell, S.J. Arch. Microbiol. 172, 269–279 (1999).

    Article  CAS  Google Scholar 

  5. Wu, L.F. et al. Nat. Genet. 31, 255–265 (2002).

    Article  CAS  Google Scholar 

  6. Chivian, E. Can. Med. Assoc. J. 164, 66–69 (2001).

    CAS  Google Scholar 

  7. Strong, K., Mathers, C., Leeder, S. & Beaglehole, R. Lancet 366, 1578–1582 (2005).

    Article  Google Scholar 

  8. Martikainen, J., Kivi, I. & Linnosmaa, I. Health Policy (New York) 74, 235–246 (2005).

    Article  Google Scholar 

  9. Chale, S.S., Swai, A.B., Mujinja, P.G. & McLarty, D.G. Br. Med. J. 304, 1215–1218 (1992).

    Article  CAS  Google Scholar 

  10. Patz, J.A., Campbell-Lendrum, D., Holloway, T. & Foley, J.A. Nature 438, 310–317 (2005).

    Article  CAS  Google Scholar 

  11. Drews, J. Nat. Biotechnol. 16 (Suppl.) 22–24 (1998).

    Article  CAS  Google Scholar 

  12. Strausberg, R.L., Simpson, A.J., Old, L.J. & Riggins, G.J. Nature 429, 469–474 (2004).

    Article  CAS  Google Scholar 

  13. Glaser, V. Nat. Biotechnol. 17, 634 (1999).

    Article  CAS  Google Scholar 

  14. Smith, J.J., Travis, S.M., Greenberg, E.P. & Welsh, M.J. Cell 85, 229–236 (1996).

    Article  CAS  Google Scholar 

  15. Singh, P.K. et al. Nature 407, 762–764 (2000).

    Article  CAS  Google Scholar 

  16. Reichart, J.M. Nat. Rev. Drug Discov. 2, 695–702 (2003).

    Article  Google Scholar 

Download references

Acknowledgements

I thank M. Cooper and B. Duft for their substantive contributions and criticism, and P.J. Scott for his helpful discussions. I acknowledge support from the Endocore Research Trust and program grants from the Foundation for Research, Science and Technology (New Zealand) and the Health Research Council of New Zealand.

Author information

Authors and Affiliations

  1. School of Biological Sciences, University of Auckland,

    Garth J S Cooper

  2. Protemix Inc.,

    Garth J S Cooper

Authors
  1. Garth J S Cooper
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cooper, G. Fates intertwined. Nat Biotechnol 24, 252–254 (2006). https://doi.org/10.1038/nbt0306-252

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0306-252

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing